Vertex's CF Three-Drug Combo Excels In Phase III, But Filing Depends On Second Regimen's Results
Executive Summary
Vertex duplicated promising efficacy observed in Phase II for its cystic fibrosis triple combo that includes VX-659, but wants to see data expected in early 2019 for a triplet containing VX-445 before filing for approvals.